Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B

Publication Details

JACC: Advances

June 2025

Access Here

Author(s)

John L Berk¹, Olivier Lairez², Pedro Schwartzmann³, Shaun Bender⁴, Matthew T White⁴, Patrick Y Jay⁴, David Danese⁴, Ronald Witteles⁵

Affiliations

¹Boston University School of Medicine, Boston, Massachusetts, USA; ²Hôpital de Rangueil, Toulouse, France; ³Advanced Research Centre (CAPED) and Unimed Hospital, Ribeirão Preto, São Paulo, Brazil; ⁴Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA; ⁵Stanford University School of Medicine, Stanford, California, USA

Abstract

Background:

Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) suffer substantial morbidity and mortality. The meaningful preservation of functional capacity and quality of life are important priorities.

Objectives:

The 6-minute walk test (6MWT), a measure of functional capacity, was the primary outcome in the APOLLO-B study of patisiran in patients with ATTR-CM; the treatment benefit vs placebo was +15 m over 12 months. We estimated the minimal clinically important difference for change in 6MWT performance.

Methods:

Change from baseline in 6MWT performance was anchored to established categories of clinically important change in the Kansas City Cardiomyopathy Questionnaire-Overall Summary score. To relate changes in 6MWT performance to activities of daily living, we fit a proportional-odds cumulative logit model for items in the Kansas City Cardiomyopathy Questionnaire Physical Limitation domain.

Results:

The APOLLO-B trial randomized 360 patients to receive placebo (n = 179) or patisiran (n = 181). The estimated minimal clinically important difference in 6MWT was 6.9 to 7.8 m. When comparing the change from baseline in 6MWT at month 12 between 2 patients, 15 m greater preservation was associated with approximately 10% to 16% lower odds of deterioration in walking 1 block (OR: 0.88 [95% CI: 0.83-0.93]), climbing stairs (OR: 0.84 [95% CI: 0.80-0.89]), hurrying/jogging (OR: 0.88 [95% CI: 0.83-0.93]), dressing oneself (OR: 0.85 [95% CI: 0.81-0.90]), and performing yard/housework or carrying groceries (OR: 0.89 [95% CI: 0.84-0.93]).

Conclusions:

In patients with ATTR-CM treated with patisiran, mean population-level differences of 7 to 8 m in 6MWT have practical relevance. The magnitude of the impact of patisiran on 6MWT performance over 12 months in APOLLO-B was associated with preserving the ability to perform activities of daily living.